Series - Scientific Developments

Following reauthorization by Congress of the SBIR/STTR Programs in 2022, there are new rules companies should familiarize themselves with concerning required disclosures of foreign affiliations or relationships with foreign countries. In addition to mandating disclosures prior to receiving SBIR awards, companies must also regularly update NIH following any changes to a disclosure. View this webinar organized by the Biotechnology Innovation Organization (BIO) for a comprehensive discussion on how to effectively navigate these new rules as you apply for SBIR awards.

This webinar is co-hosted by the National Institutes of Health (NIH) Seed Office.

With the majority of biological studies conducted in academic settings but nearly all innovative new drug clinical trials sponsored by industry, improving translational research success rates for commercialization is critical to bringing new treatments to patients. Surveys of academic tech transfer offices and the biopharma industry executives working on such alliances cite as obstacles two highly controllable factors: disagreement about alliance performance metrics and misalignment of deal terms priorities. This panel discusses best practices for removing such obstacles to accelerate more promising ideas into clinical development for patients.

BIO's updated 2023 report, "U.S. Biotechnology Translational Research: Partnership Models, Management Principles, and Best Practices," is available for download at the link below.  The webinar also summarizes major findings from that BIO report as context for the panel discussion and audience Q&A.

View this important webinar for those invested in the broader biotech industry, "Understanding the Business Implications of Global Access and Benefit Sharing Policies." Tailored for members of BIO and a diverse community of stakeholders, this high-level session focuses on understanding the impact of recent developments in the global policy arena that will affect industry’s access to vital biologic materials and information. These policies have implications for the way industry will need to share the potential benefits that flow from their use of these physical and digital resources worldwide. Through interactive discussions led by seasoned experts across the Biotech ecosystem, explore the intricate relationship between national and global concerns, while uncovering the potential implications for your company. This webinar will equip you with the knowledge and insights essential to thriving in an ever-evolving global biotech landscape for an empowering dialogue that promises to shape the future of biotechnology.

The BIO Investor Forum is back! Join us at the Hilton San Francisco Union Square from October 17-18 for two days of thought-leadership, partnering, and insight into investment trends and the priorities of venture-stage growth and emerging public biotech companies.

View this webinar to learn more about what’s happening this year, including a half-day pre-conference event, the BIO Seed-Stage Spotlight on Tech Transfer with 34 fast pitches from start-ups outlining their drug development programs.  This webinar will detail what the BIO One-on-One Partnering™ system can do for your business goals and how to use the system's powerful features.  Explore the program, networking opportunities, partnering system fundamentals, gain insight into best practices for partnering, and more.

For more information and to register for the BIO Investor Forum, please visit: https://www.bio.org/events/bio-investor-forum

Register now for the conference to get access to the partnering system and to request your meetings.

The Cell and Gene Therapy (CGT) Science Series is a quarterly seminar series focused on scientific topics related to cell and gene therapy products. The CGT Science Series is intended to foster scientific exchange between the Biotechnology Innovation Organization (BIO), the American Society of Cell & Gene Therapy (ASGCT), and Center for Biologics Evaluation and Research (CBER) review staff on a variety of topics that span the CGT product lifecycle. The seminars are planned as 60-minute virtual webinars featuring a speaker from one of the three organizations. The CGT Science Series will enable a deep dive into a specific technical and/or scientific area. Topics in the series may include but are not limited to, nonclinical, CMC, clinical, or post-market phases of development related to CGT product lifecycle.

Moderator:
– Anne-Virginie Eggimann, Tessera

Opening Remarks:
– Cartier Esham, Senior Advisor, Biotechnology Innovation Organization (BIO)

Speaker:
– Jing Liao, Director, Vector Development and Operations, Alexion Pharmaceuticals

View this webinar to learn about the many exciting opportunities available at the 2023 BIO Asia-Taiwan International Conference & Exhibition. This webinar covers:

- Overview of the event schedule
- Preview of conference sessions and programming
- Live demo of the BIO One-on-One Partnering system, including new features such as Optional Meeting Participants, to enhance your business partnering experience
- Q&A with the speakers

Conference details at this link.

This webinar is for BIO 2023 attendees who are familiar with the BIO One-on-One Partnering™ system and want to use the platform more effectively. View this advanced partnering webinar—led by BIO’s Director of Partnering—to learn tips & tricks, commonly overlooked yet powerful features that will help you better identify companies of interest, and more. You can leverage these insights and features to take your partnering experience to the next level in Boston at this year's BIO International Convention.

Learn more and register for BIO 2023 at this link.

During this webinar, panelists discuss strategies for biotechnology companies to manage economic downturns and weakened investor interest in the biotech industry. Our expert panel of industry leaders share their insights and experiences on how to maintain momentum and emerge stronger during periods of economic uncertainty.

This webinar is designed to provide practical advice and actionable strategies that can be implemented immediately. The panel covers the following topics:

• Effective communication and investor relations strategies during economic downturns

• Actions biotechs can take to cut costs without sacrificing innovation and growth

• How to pitch to investors during weakened investor interest periods

U.S. Department of Justice (DOJ) statistics suggest that enforcement will be a top government priority in 2023, including for pharma/life sciences. Warning or untitled letters from the U.S. Food and Drug Administration (FDA) will serve as ammunition for DOJ cases. Statements about product safety will be heavily scrutinized.

Do you know what to watch out for? Has your company trained its employees and marketing agencies on how to appropriately implement the requirements for promotion? What activities require extra vigilance? The prior downturn in enforcement can be linked to the development of a response to COVID-19, which diverted government resources across the board. Now trends suggest the FDA, DOJ, and Office of Inspector General (OIG) will return to active healthcare enforcement in 2023 for violations of the Food Drug and Cosmetic Act (FDCA), False Claims Act and the Anti-Kickback Statute in part attributable to the goal of obtaining additional financial recoveries.

This webinar hosted by the Biotechnology Innovation Organization (BIO) has these learning objectives:
—Understand the current trends for government enforcement
—Dissect the compliance implications of increased enforcement on the industry
—Identify specific cases that are clear examples for company concern
—Isolate the key principles for avoiding violations

ON-DEMAND
COMMUNICATIONS COMPLIANCE COURSES
FOR PROFESSIONAL DEVELOPMENT

Special Discount
Buy 2 course registrations, Get 1 FREE
through May 15, 2023
in honor of this webinar!

The Center for Communication Compliance (CCC) helps biopharmaceutical companies achieve efficient, compliant innovation in a digital world through its proprietary on-demand business solutions in education, technology, and change management.

The CCC eLearning System has set an unmatched standard for confirming regulatory competency through engaging mastery tests and expert education content across more than a dozen course options.

SEE COURSES LIST